Resverlogix Past Earnings Performance
Past criteria checks 0/6
Resverlogix's earnings have been declining at an average annual rate of -63.5%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-63.5%
Earnings growth rate
-65.5%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Resverlogix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -11 | 2 | 2 |
| 30 Jun 24 | 0 | -11 | 2 | 2 |
| 31 Mar 24 | 0 | -10 | 3 | 2 |
| 31 Dec 23 | 0 | -17 | 3 | 2 |
| 30 Sep 23 | 0 | -13 | 3 | 2 |
| 30 Jun 23 | 0 | -10 | 4 | 3 |
| 31 Mar 23 | 0 | -6 | 4 | 3 |
| 31 Dec 22 | 0 | -4 | 7 | 4 |
| 30 Sep 22 | 0 | -21 | 11 | 5 |
| 30 Jun 22 | 0 | -25 | 14 | 5 |
| 31 Mar 22 | 0 | -27 | 15 | 5 |
| 31 Dec 21 | 0 | -25 | 11 | 5 |
| 31 Dec 20 | 0 | 2 | 8 | 6 |
| 31 Oct 20 | 0 | 4 | 8 | 5 |
| 31 Jul 20 | 0 | 108 | 8 | 9 |
| 30 Apr 20 | 0 | 118 | 7 | 15 |
| 31 Jan 20 | 0 | 49 | 7 | 24 |
| 31 Oct 19 | 0 | 31 | 7 | 30 |
| 31 Jul 19 | 0 | -109 | 7 | 33 |
| 30 Apr 19 | 0 | -163 | 7 | 32 |
| 31 Jan 19 | 0 | -110 | 6 | 33 |
| 31 Oct 18 | 0 | -121 | 5 | 37 |
| 31 Jul 18 | 0 | -92 | 4 | 36 |
| 30 Apr 18 | 0 | -58 | 4 | 37 |
| 31 Jan 18 | 0 | -62 | 4 | 37 |
| 31 Oct 17 | 0 | -51 | 4 | 33 |
| 31 Jul 17 | 0 | -55 | 4 | 32 |
| 30 Apr 17 | 0 | -46 | 4 | 30 |
| 31 Jan 17 | 0 | -44 | 4 | 27 |
| 31 Oct 16 | 0 | -40 | 4 | 22 |
| 31 Jul 16 | 0 | -29 | 4 | 19 |
| 30 Apr 16 | 0 | -20 | 4 | 15 |
| 31 Jan 16 | 0 | -30 | 4 | 11 |
| 31 Oct 15 | 0 | -23 | 4 | 8 |
| 31 Jul 15 | 0 | -22 | 5 | 6 |
| 30 Apr 15 | 0 | -18 | 4 | 4 |
| 31 Jan 15 | 0 | 2 | 4 | 4 |
| 31 Oct 14 | 0 | 19 | 4 | 4 |
| 31 Jul 14 | 0 | 20 | 4 | 4 |
| 30 Apr 14 | 0 | 55 | 4 | 9 |
Quality Earnings: 0VF9 is currently unprofitable.
Growing Profit Margin: 0VF9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0VF9 is unprofitable, and losses have increased over the past 5 years at a rate of 63.5% per year.
Accelerating Growth: Unable to compare 0VF9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0VF9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0VF9's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.